Medicine composition used for treating eczema, and preparation method thereof

A composition and drug technology, applied in the field of medicine, can solve the problems of large side effects, roughness, dry skin, etc., and achieve the effect of reducing the level of histamine in eczema skin, sterilizing the level of histamine in eczema skin, and fast and strong healing effect

Active Publication Date: 2013-06-26
福州中科伟创生物科技有限公司
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Due to the use of in vitro supplementation of glucocorticoids in the treatment of eczema, these drugs have large side effects and are used repeatedly, prone to skin...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] 1) Weigh the components of the oil phase as follows and put them into the oil phase container to obtain the oil phase mixture A: 2.0 kg of white beeswax, 12.0 kg of white oil, 4.0 kg of C12-15 benzoate, 2.0 kg of isopropyl myristate , 2.0 kg lanolin, 3.0 kg shea butter, 2.0 kg DC250 dimethicone, 0.3 kg vitamin E, 0.1 kg methyl paraben, 0.2 kg ethyl paraben, 3.0 kg PEG-30 dipolyhydroxy Stearate, oil phase components are added to the oil phase container.

[0041]Weigh the components of the water phase as follows and put them into the oil phase container to obtain the water phase mixture B: 5.0 kg of glycerin, 1.2 kg of magnesium sulfate heptahydrate, 1.0 kg of diphenhydramine hydrochloride, 57.0 kg of purified water, and the components of the water phase Add to water phase container.

[0042] The pharmaceutical active component is weighed as follows and thrown into the pharmaceutical active component container to obtain the pharmaceutical active component mixture C: 4.0 ...

Embodiment 2

[0049] 1) Weigh the components of the oil phase as follows and put them into the oil phase container to obtain the oil phase mixture A: 1 kg of white beeswax, 10 kg of white oil, 3 kg of C12-15 benzoate, 1 kg of isopropyl myristate , 1 kg lanolin, 2 kg shea butter, 1 kg DC250 dimethicone, 0.3 kg vitamin E, 0.1 kg methyl paraben, 0.2 kg ethyl paraben, 3 kg PEG-30 dipolyhydroxy Stearate, oil phase components are added to the oil phase container.

[0050] Weigh the components of the water phase as follows and put them into the oil phase container to obtain the water phase mixture B: 4 kg of glycerin, 0.8 kg of magnesium sulfate heptahydrate, 0.8 kg of diphenhydramine hydrochloride, 55 kg of purified water, and the components of the water phase Add to water phase container.

[0051] The pharmaceutically active component is thrown into the pharmaceutically active component container by weighing the following to obtain the pharmaceutically active component mixture C: 3 kilograms of...

Embodiment 3

[0058] 1) Weigh the components of the oil phase as follows and pour them into the oil phase container to obtain the oil phase mixture A: 3 kg of white beeswax, 14 kg of white oil, 5 kg of C12-15 benzoate, 3 kg of isopropyl myristate , 3 kg lanolin, 4 kg shea butter, 3 kg DC250 dimethicone, 0.5 kg vitamin E, 0.1 kg methyl paraben, 0.2 kg ethyl paraben, 3 kg PEG-30 dipolyhydroxy Stearate, oil phase components are added to the oil phase container.

[0059] Weigh the components of the water phase as follows and put them into the oil phase container to obtain the water phase mixture B: 6 kg of glycerin, 1.2 kg of magnesium sulfate heptahydrate, 1.2 kg of diphenhydramine hydrochloride, 60 kg of purified water, and the components of the water phase Add to water phase container.

[0060] The pharmaceutically active component is thrown into the pharmaceutically active component container according to the following weighing to obtain the pharmaceutically active component mixture C: 5 k...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and relates to a medicine composition used for treating eczema, and a preparation method thereof. The eczema-treating medicine composition is obtained by mixing the raw materials of, by weight, 1-3 parts of white beeswax, 10-14 parts of white oil, 3-5 parts of C12-15 benzoate, 1-3 parts of isopropyl myristate, 1-3 parts of lanolin, 2-4 parts of shea butter, 1-3 parts of DC250 dimethyl silicone oil, 0.1 parts of methylparaben, 0.2 parts of ethylparaben, 2-4 parts of PEG-30 dimeric hydroxyl stearate, and the like. The eczema-treating medicine composition provided by the invention has fast and high treatment effect, and good nursing effect. Once eczema is cured by using the medicine composition, reoccurrence is prevented. The medicine composition also has three effects such as itching relieving and inflammation eliminating, sterilizing, and eczema skin histamine level reducing. As a result of experiments, the medicine composition has an ideal treatment effect against eczema patient symptoms such as erythema, skin lesions and itching.

Description

technical field [0001] The technical field of medicine of the present invention relates to a pharmaceutical composition for treating eczema and a preparation method thereof. Background technique [0002] Eczema is a pleomorphic skin lesion and exudative inflammatory reaction caused by internal and external factors such as heredity and immunity. The main symptoms are itching and skin lesions. [0003] At present, there are many methods for treating eczema at home and abroad. For itchy eczema, 1% hydrocortisone cream, 0.5% hydrocortisone butyrate ointment, 0.1% triamcinolone acetonide cream and other local application methods are generally used; for exudative inflammation caused by skin lesions For patients, apply 2% mupirocin ointment, 0.05% berberine cream, and 1% erythromycin ointment to prevent secondary bacterial infection. [0004] Due to the use of in vitro supplementation of glucocorticoids in the treatment of eczema, these drugs have large side effects and are used ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/534A61K31/56A61K47/44A61P17/00A61K31/045A61K31/047A61K31/12
Inventor 吴燕斌肖永堂
Owner 福州中科伟创生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap